An accelerated shift in the use of remote systems in epilepsy due to the COVID-19 pandemic.
Adult
Africa
Aged
Asia
Attitude of Health Personnel
Betacoronavirus
COVID-19
China
Computer Security
Confidentiality
Coronavirus Infections
Cross-Sectional Studies
Education, Distance
/ trends
Epilepsy
/ therapy
Europe
Female
France
Humans
Italy
Male
Middle Aged
Neurologists
Neurology
North America
Pandemics
Pneumonia, Viral
Practice Patterns, Physicians'
Remote Consultation
/ trends
SARS-CoV-2
South America
Surveys and Questionnaires
Telemedicine
/ trends
E-health
E-learning
Remote work system
Teleconsultations
Telemedicine
Virtual meeting
Journal
Epilepsy & behavior : E&B
ISSN: 1525-5069
Titre abrégé: Epilepsy Behav
Pays: United States
ID NLM: 100892858
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
14
07
2020
revised:
24
07
2020
accepted:
24
07
2020
pubmed:
4
9
2020
medline:
27
11
2020
entrez:
4
9
2020
Statut:
ppublish
Résumé
The purpose of the study was to describe epileptologists' opinion on the increased use of remote systems implemented during the COVID-19 pandemic across clinics, education, and scientific meetings activities. Between April and May 2020, we conducted a cross-sectional, electronic survey on remote systems use before and during the COVID-19 pandemic through the European reference center for rare and complex epilepsies (EpiCARE) network, the International and the French Leagues Against Epilepsy, and the International and the French Child Neurology Associations. After descriptive statistical analysis, we compared the results of France, China, and Italy. One hundred and seventy-two respondents from 35 countries completed the survey. Prior to the COVID-19 pandemic, 63.4% had experienced remote systems for clinical care. During the pandemic, the use of remote clinics, either institutional or personal, significantly increased (p < 10 The COVID-19 pandemic has dramatically altered how academic epileptologists carry out their core missions of clinical care, medical education, and scientific discovery and dissemination. Close attention to the impact of these changes is merited.
Identifiants
pubmed: 32882627
pii: S1525-5050(20)30555-2
doi: 10.1016/j.yebeh.2020.107376
pmc: PMC7457939
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107376Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure of conflicts of interest M. Kuchenbuch, G D'Onofrio, Y. Jiang, ZM Grinspan, J Wilmshurst and R Nabbout have any conflict of interest to disclose. S Dupont has received honoria from EISAI, UCB, GW, Novartis, Advicenne and Shire. E Wirrell has acted as an investigator for GW Pharma and Zogenix and has received consulting fees from Biocodex and Biomarin. S Auvin has served as consultant or received honoraria for lectures from Arvelle therapeutics, Biocodex, Eisai, GW Pharma, Novartis, Nutricia, UCB Pharma, Zogenyx. He has been investigator for clinical trials for Advicenne Pharma, Eisai, UCB Pharma and Zogenyx. A Arzimanoglou has served as consultant, received honoraria for lectures from Arvelle therapeutics, Eisai, GW Pharma, UCB Pharma and Zogenix. On behalf of his Instiitution he has been investigator for clinical trials sponsored by Eisai, GW, UCB Pharma and Zogenix. JH Cross has acted as an investigator for studies with GW Pharma, Zogenix, Vitaflo and Marinius. She has been a speaker and on advisory boards for GW Pharma, Zogenix, and Nutricia; all remuneration has been paid to her department. Her research is supported by the National Institute of Health Research (NIHR) Biomedical Research Centre at Great Ormond Street Hospital, NIHR, EPSRC, GOSH Charity, ERUK, the Waterloo Foundation. N Specchio has acted as an investigator for studies with Zogenix, Marinus, Biomarin, and Livanova, and has received consulting fees from Zogenix, Biomarin, Arvelle, Livanova.